Managing Intrathecal Drug Delivery (ITDD) in Cancer Patients

被引:10
作者
Shah, Rajiv [1 ]
Baqai-Stern, Aisha [2 ]
Gulati, Amitabh [2 ]
机构
[1] New York Presbyterian Hosp, Weill Cornell Med Coll, Dept Anesthesiol, New York, NY USA
[2] Mem Sloan Kettering Canc Ctr, Dept Anesthesiol & Crit Care, Board Certified Anesthesiol & Pain Management, M308, New York, NY 10065 USA
关键词
Intrathecal drug delivery; Intrathecal medications; Cancer pain; Neuraxial trial; CHRONIC PAIN; MANAGEMENT; RECOMMENDATIONS; SELECTION; THERAPY; SYSTEM; IMPACT;
D O I
10.1007/s11916-015-0488-x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Pain is a commonly reported symptom in cancer patients. Patients with cancer pain often fail conservative medical management or have significant side effects to systemic medications. The implantation of an intrathecal drug delivery (ITDD) system may be the most effective treatment option for these patients and can improve their quality of life. This article aims to discuss the choice of intrathecal medications for patients suffering from intractable cancer pain, the management of ITDD throughout a patient's disease course, and the management of complications related to the ITDD system and intrathecal medications.
引用
收藏
页数:5
相关论文
共 50 条
  • [1] Managing Intrathecal Drug Delivery (ITDD) in Cancer Patients
    Rajiv Shah
    Aisha Baqai-Stern
    Amitabh Gulati
    Current Pain and Headache Reports, 2015, 19
  • [2] Bolus Intrathecal Injection of Ziconotide (Prialt®) to Evaluate the Option of Continuous Administration via an Implanted Intrathecal Drug Delivery (ITDD) System: A Pilot Study
    Mohammed, Salma I.
    Eldabe, Sam
    Simpson, Karen H.
    Brookes, Morag
    Madzinga, Grace
    Gulve, Ashish
    Baranidharan, Ganesan
    Radford, Helen
    Crowther, Tracey
    Buchser, Eric
    Perruchoud, Christophe
    Batterham, Alan Mark
    NEUROMODULATION, 2013, 16 (06): : 576 - 582
  • [3] Initiation of Intrathecal Drug Delivery Dramatically Reduces Systemic Opioid Use in Patients With Advanced Cancer
    Sindt, Jill E.
    Odell, Daniel W.
    Dalley, Andrew P.
    Brogan, Shane E.
    NEUROMODULATION, 2020, 23 (07): : 978 - 983
  • [4] Intrathecal Drug Delivery Systems for Cancer Pain Control: Insights on Current Contemporary Practices in the US
    Goel, Vasudha
    Kumar, Varun
    Blaes, Anne
    Gulati, Amitabh
    NEUROMODULATION, 2023, 26 (06): : 1256 - 1262
  • [5] Intrathecal Drug Delivery for the Treatment of Cancer-Associated Chronic Pain in Children
    Kenfield, Meaghan
    Zacharias, Nicholas
    Abd-Elsayed, Alaa
    NEUROMODULATION, 2021, 26 (06): : 1153 - 1163
  • [6] Surgical Site Infections in Cancer Patients with Intrathecal Drug Delivery Devices
    Scanlon, Maura M.
    Gazelka, Halena M.
    Moeschler, Susan M.
    Hoelzer, Bryan C.
    Hooten, W. Michael
    Bendel, Markus A.
    Lamer, Tim J.
    PAIN MEDICINE, 2017, 18 (03) : 520 - 525
  • [7] Advances in intrathecal drug delivery
    De Andres, Jose
    Asensio-Samper, Juan M.
    Fabregat-Cid, Gustavo
    CURRENT OPINION IN ANESTHESIOLOGY, 2013, 26 (05) : 594 - 599
  • [8] Complications of intrathecal drug delivery therapy (ITDD): A retrospective study of 231 implantations between 1999 and 2014
    Necking, Erik
    Levi, Richard
    Ertzgaard, Per
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2021, 205
  • [9] History and Present State of Targeted Intrathecal Drug Delivery
    Rizvi, Syed
    Kumar, Krishna
    CURRENT PAIN AND HEADACHE REPORTS, 2015, 19 (02)
  • [10] Attitudes of Hospice Providers Regarding Intrathecal Targeted Drug Delivery for Patients With Cancer
    Warner, Lindsay L.
    Moeschler, Susan S.
    Pittelkow, Thomas P.
    Strand, Jacob J.
    AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE, 2019, 36 (11) : 955 - 958